Vossen ARJV, et al. - Experts assessed the effectiveness and short-term safety of apremilast in patients with moderate hidradenitis suppurativa (HS). Clinically meaningful efficacy was demonstrated by apremilast at a dose of 30 mg twice daily and was generally well tolerated in patients with moderate HS. The two treatment groups did not demonstrate any significant difference in the DLQI over time. In the apremilast-treated patients, the most frequently reported adverse events were mild to moderate headache and gastro-intestinal symptoms, which have not resulted in drop-outs.